The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Antipsychotic medication in schizophrenia: a review
Open accessAbstract
INTRODUCTION: Antipsychotic medications are mainstays in the treatment of schizophrenia and a range of other psychotic disorders. SOURCES OF DATA: Recent meta-analyses of antipsychotic efficacy and tolerability have been included in this review, along with key papers on antipsychotic use in schizophrenia and other psychotic illnesses. AREAS OF AGREEMENT: The heterogeneity in terms of individuals' response to antipsychotic treatment and the current inability to predict response leads to a trial-and-error strategy with treatment choice. Clozapine is the only effective medication for treatment-resistant schizophrenia. AREAS OF CONTROVERSY: There are a significant number of side effects associated with antipsychotic use. With a reduction in the frequency of extrapyramidal side effects with the use of second-generation antipsychotics, there has been a significant shift in the side effect burden, with an increase in the risk of cardiometabolic dysfunction. GROWING POINTS: There exist small and robust efficacy differences between medications (other than clozapine), and response and tolerability to each antipsychotic drug vary, with there being no first-line antipsychotic drug that is suitable for all patients. AREAS TIMELY FOR DEVELOPING RESEARCH: A focus on the different symptom domains of schizophrenia may lead to endophenotypic markers being identified, e.g. for negative symptoms and cognitive deficits (as well as for positive symptoms) that can promote the development of novel therapeutics, which will rationally target cellular and molecular targets, rather than just the dopamine 2 receptor. Future developments will target additional processes, including glutamatergic, cholinergic and cannabinoid receptor targets and will utilize personalized medicine techniques, such as pharmacogenetic variants and biomarkers allowing for a tailored and safer use of antipsychotics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · cited 1×
“In a more recent meta-analysis, the separation of antipsychotic medications into FGA and SGA groupings has been further called into question, with similar efficacy between the groups seen.(10) The most efficacious antipsychotics in this meta-analysis were the SGAs that were first developed, with small but robust diffe…”
ResultAntipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Second-Generation (Atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,340
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Jones, P. B., Barnes, T. R. E., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R. M., Markwick, A., & Lewis, S. W. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,105
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Mitchell, A. J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., & De Hert, M. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr148 · Cited by 1,082
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931 · cited 1×
“This showed that antipsychotics had a relapse rate of 28% compared with a relapse rate of 64% for placebo over a 7–12-month follow-up period.(8) The effect size is comparable with that seen for many treatments for non-psychiatric disorders, such as hypertension, hypercholesterolaemia and type 2 diabetes.”
ResultSchizophrenia: an integrated sociodevelopmental-cognitive model
Howes, O. D., & Murray, R. M. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62036-x · Cited by 864
Compliance With Medication Regimens for Mental and Physical Disorders
Cramer, J. A., & Rosenheck, R. (1998) · Psychiatric Services · doi:10.1176/ps.49.2.196 · Cited by 725
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
Cipriani, A., Barbui, C., Salanti, G., Rendell, J., Brown, R., Stockton, S., Purgato, M., Spineli, L. M., Goodwin, G. M., & Geddes, J. R. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60873-8 · Cited by 631
Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081224 · Cited by 619
Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094112 · Cited by 490 · cited 1×
“The most dramatic weight gain is seen in antipsychotic naïve patients over the first 6 weeks of treatment and for the majority, those with initial weight gain did not lose that weight thereafter, even after switching to more weight-neutral antipsychotics.(14) SGAs such as aripiprazole, lurasidone and asenapine have a…”
BackgroundLeucht, S., Hierl, S., Kissling, W., Dold, M., & Davis, J. M. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.096594 · Cited by 451 · cited 1×
“The effect size is comparable with that seen for many treatments for non-psychiatric disorders, such as hypertension, hypercholesterolaemia and type 2 diabetes.(9) This indicates that antipsychotic medications are not less effective when prescribed for their target conditions, than those used by other medical specialt…”
ResultDelayed-Onset Hypothesis of Antipsychotic Action: A Hypothesis Tested and Rejected
Agid, O., Kapur, S., Arenovich, T., & Zipursky, R. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.12.1228 · Cited by 408
Correll, C. U., Rummel-Kluge, C., Corves, C., Kane, J. M., & Leucht, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn018 · Cited by 397
Kapur, S., & Remington, G. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01251-3 · Cited by 390
Howes, O. D., Vergunst, F., Gee, S., McGuire, P., Kapur, S., & Taylor, D. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.105833 · Cited by 353
Treatment of the Neuroleptic-Nonresponsive Schizophrenic Patient
Meltzer, H. Y. (1992) · Schizophrenia Bulletin · doi:10.1093/schbul/18.3.515 · Cited by 332
The Maudsley Prescribing Guidelines in Psychiatry (Full-Text Access)
(2025) · The Maudsley Prescribing Guidelines in Psychiatry · doi:10.1002/9781119870203.mpg016 · Cited by 290
British National Formulary: BNF
Press, P. (2015) · doi:10.18578/bnf.147942626 · Cited by 269
Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia.
Leucht, S., & Heres, S. (2006) · PubMed · Cited by 223
Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia
Rosenheck, R. A., Krystal, J. H., Lew, R., Barnett, P. G., Fiore, L., Valley, D., Thwin, S. S., Vertrees, J. E., & Liang, M. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1005987 · Cited by 214
Masand, P. S., Roca, M., Turner, M. S., & Kane, J. M. (2009) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.08r00612 · Cited by 161
Role of Dopamine D2 Receptors for Antipsychotic Activity
Ginovart, N., & Kapur, S. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_2 · Cited by 159
Challenges in the Treatment of Major Depressive Disorder With Psychotic Features
Rothschild, A. J. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt046 · Cited by 154
Crawford, M., Jayakumar, S., Lemmey, S. J., Zalewska, K., Patel, M. X., Cooper, S. J., & Shiers, D. (2014) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.113.142521 · Cited by 128
Valenstein, M. M., Kavanagh, J., Lee, T. A., Reilly, P., Dalack, G. W., Grabowski, J., Smelson, D. A., Ronis, D. L., Ganoczy, D. A., Woltmann, E. M., et al. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp121 · Cited by 95
Citrome, L. (2013) · CNS Drugs · doi:10.1007/s40263-013-0105-7 · Cited by 94
Girgis, R. R., Phillips, M. R., Li, X., Li, K., Jiang, H., Wu, C., Duan, N., Niu, Y., & Lieberman, J. A. (2011) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.110.081471 · Cited by 73
Asenapine review, part II: clinical efficacy, safety and tolerability
Citrome, L. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.908183 · Cited by 42
A case of paliperidone-palmitate-induced tardive dyskinesia
Lally, J., Byrne, F., & Walsh, E. (2012) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2012.04.009 · Cited by 7
Self-citation
Cited by
Aggression in autism spectrum disorder: presentation and treatment options
Fitzpatrick, S., Srivorakiat, L., Wink, L., Pedapati, E., & Erickson, C. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s84585 · Cited by 271
Ross, S., Agin-Liebes, G., Lo, S., Zeifman, R. J., Ghazal, L., Benville, J., Franco Corso, S., Bjerre Real, C., Guss, J., Bossis, A., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00020 · Cited by 139
Rotella, F., Cassioli, E., Calderani, E., Lazzeretti, L., Ragghianti, B., Ricca, V., & Mannucci, E. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.12.118 · Cited by 48
Pharmacogenomic Biomarkers and Their Applications in Psychiatry
Kam, H., & Jeong, H. (2020) · Genes · doi:10.3390/genes11121445 · Cited by 37
Köhler, O., Sylvia, L. G., Bowden, C. L., Calabrese, J. R., Thase, M., Shelton, R. C., McInnis, M., Tohen, M., Kocsis, J. H., Ketter, T. A., et al. (2017) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416644508 · Cited by 33
Metadata
- Authors
- Lally, J., & MacCabe, J. H.
- Venue
- British Medical Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-05-08
- Volume
- 114
- Issue
- 1
- Pages
- 169-179
- ISSN
- 0007-1420 (ISSN-L)
- 1471-8391
- OpenAlex
- W2317070629
- Cited by
- 513
- References
- 37
- FWCI
- 19.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.